129 related articles for article (PubMed ID: 32481524)
21. One-carbon metabolizing enzyme ALDH1L1 influences mitochondrial metabolism through 5-aminoimidazole-4-carboxamide ribonucleotide accumulation and serine depletion, contributing to tumor suppression.
Sasaki M; Yamamoto K; Ueda T; Irokawa H; Takeda K; Sekine R; Itoh F; Tanaka Y; Kuge S; Shibata N
Sci Rep; 2023 Aug; 13(1):13486. PubMed ID: 37596270
[TBL] [Abstract][Full Text] [Related]
22. Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.
Chakrabarti G
Radiat Oncol; 2015 Jul; 10():145. PubMed ID: 26173780
[TBL] [Abstract][Full Text] [Related]
23. Ablation of insulin receptor substrates 1 and 2 suppresses
Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
[TBL] [Abstract][Full Text] [Related]
24. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
25. miR-301a promotes lung tumorigenesis by suppressing Runx3.
Li X; Zhong M; Wang J; Wang L; Lin Z; Cao Z; Huang Z; Zhang F; Li Y; Liu M; Ma X
Mol Cancer; 2019 May; 18(1):99. PubMed ID: 31122259
[TBL] [Abstract][Full Text] [Related]
26. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
27. Knockout of Putative Tumor Suppressor Aldh1l1 in Mice Reprograms Metabolism to Accelerate Growth of Tumors in a Diethylnitrosamine (DEN) Model of Liver Carcinogenesis.
Krupenko NI; Sharma J; Fogle HM; Pediaditakis P; Strickland KC; Du X; Helke KL; Sumner S; Krupenko SA
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203215
[TBL] [Abstract][Full Text] [Related]
28. ALDH1L1 and ALDH1L2 Folate Regulatory Enzymes in Cancer.
Krupenko SA; Krupenko NI
Adv Exp Med Biol; 2018; 1032():127-143. PubMed ID: 30362096
[TBL] [Abstract][Full Text] [Related]
29. The folate metabolic enzyme ALDH1L1 is restricted to the midline of the early CNS, suggesting a role in human neural tube defects.
Anthony TE; Heintz N
J Comp Neurol; 2007 Jan; 500(2):368-83. PubMed ID: 17111379
[TBL] [Abstract][Full Text] [Related]
30. Synergy of WEE1 and mTOR Inhibition in Mutant
Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
[No Abstract] [Full Text] [Related]
31. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
32. A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Dompe N; Klijn C; Watson SA; Leng K; Port J; Cuellar T; Watanabe C; Haley B; Neve R; Evangelista M; Stokoe D
PLoS One; 2018; 13(6):e0199264. PubMed ID: 29912950
[TBL] [Abstract][Full Text] [Related]
33. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
34. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
35. Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ; Mei Y; Sun S; Zhang H; Yang AJ; Mao L
Theranostics; 2016; 6(1):65-77. PubMed ID: 26722374
[TBL] [Abstract][Full Text] [Related]
36. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
37. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
38. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
